GLENMARK:NSE-Glenmark Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 499.05

Change

-6.40 (-1.27)%

Market Cap

INR 144.64B

Volume

1.36M

Avg Analyst Target

INR 598.33 (+19.89%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Glenmark Pharmaceuticals Limited (GLENMARK) Stock Analysis:
Based on the Glenmark Pharmaceuticals Limited stock forecasts from 9 analysts, the average analyst target price for Glenmark Pharmaceuticals Limited is INR 598.33 over the next 12 months. Glenmark Pharmaceuticals Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Glenmark Pharmaceuticals Limited is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Glenmark Pharmaceuticals Limited’s stock price was INR 499.05. Glenmark Pharmaceuticals Limited’s stock price has changed by -33.15 % over the past week, -15.45 % over the past month and -0.83 % over the last year.

About

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of der ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-14.45 (-1.89%)

INR1,802.02B 29.90 18.16
DIVISLAB:NSE Divi's Laboratories Limited

-20.25 (-0.42%)

INR1,261.56B 59.12 39.14
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-66.25 (-1.42%)

INR776.46B 39.30 18.49
PEL:NSE Piramal Enterprises Limited

+10.00 (+0.40%)

INR569.14B 51.84 13.88
CADILAHC:NSE Cadila Healthcare Limited

-0.10 (-0.02%)

INR465.19B 9.83 13.63
ALKEM:NSE Alkem Laboratories Limited

-34.40 (-0.99%)

INR419.28B 24.14 18.09
LUPIN:NSE Lupin Limited

-2.60 (-0.30%)

INR405.69B 25.10 31.48
AUROPHARMA:NSE Aurobindo Pharma Limited

+0.60 (+0.09%)

INR383.73B 7.58 4.70
LAURUSLABS:NSE Laurus Labs Limited

-5.40 (-1.04%)

INR272.70B 27.23 17.58
IPCALAB:NSE Ipca Laboratories Limited

-32.20 (-1.55%)

INR268.65B 52.59 17.98

ETFs Containing GLENMARK

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.71% 42% F 18% F
Dividend Return 0.50% 43% F 24% F
Total Return -0.21% 42% F 18% F
Trailing 12 Months  
Capital Gain -0.83% 35% F 13% F
Dividend Return 0.50% 38% F 21% F
Total Return -0.34% 35% F 13% F
Trailing 5 Years  
Capital Gain -42.10% 9% F 21% F
Dividend Return 1.28% 28% F 13% F
Total Return -40.82% 9% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain 1.09% 11% F 28% F
Dividend Return 0.44% 46% F 34% F
Total Return 1.54% 11% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 42.38% 69% D+ 68% D+
Risk Adjusted Return 3.63% 14% F 28% F
Market Capitalization 144.64B 81% B- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.46 73% C 64% D
Price/Book Ratio 1.67 73% C 56% F
Price / Cash Flow Ratio 12.79 59% F 37% F
EV/EBITDA 7.31 81% B- 71% C-
Management Effectiveness  
Return on Equity 13.73% 50% F 59% F
Return on Invested Capital 10.97% 50% F 72% C-
Return on Assets 7.47% 54% F 72% C-
Debt to Equity Ratio 55.05% 6% F 23% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.05 34% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector